Medtronic InFuse Favored By Study Data, New Payment Code In The Offing
This article was originally published in The Gray Sheet
Executive Summary
The Centers for Medicare & Medicaid Services should consider a separate ICD-9-CM code for Medtronic's InFuse BMP-2 bone morphogenetic protein pending FDA approval of the device, according to the agency's ICD-9 Coordination and Maintenance Committee
You may also be interested in...
Medtronic Seals FDA Panel Endorsement With InFuse Bone Growth Product
Preclinical studies of the effects of recombinant human bone morphogenetic protein-2 (rhBMP-2) on tumorogenicity, dosing and antibody response during pregnancy should be conducted by Medtronic/Sofamor Danek, FDA's Orthopedic & Rehabilitation Devices Panel recommended Jan. 10
Off-Label Concerns With InFuse Raised, But Panel Decides Against Bundling
Medtronic/Sofamor Danek successfully avoided a proposed condition that would have bundled its LT-Cage lumbar tapered fusion device with its InFuse bone graft during FDA's Orthopedic & Rehabilitation Devices Panel review Jan. 10
Medtronic Seals FDA Panel Endorsement With InFuse Bone Growth Product
Preclinical studies of the effects of recombinant human bone morphogenetic protein-2 (rhBMP-2) on tumorogenicity, dosing and antibody response during pregnancy should be conducted by Medtronic/Sofamor Danek, FDA's Orthopedic & Rehabilitation Devices Panel recommended Jan. 10